Edgar Filing: ACORDA THERAPEUTICS INC - Form 4

ACORDA THERAPEUTICS INC Form 4 December 22, 2015 OMB APPROVAL FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... 0.5 Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading LAWRENCE DAVID Issuer Symbol ACORDA THERAPEUTICS INC (Check all applicable) [ACOR] (Last) (First) (Middle) 3. Date of Earliest Transaction Director 10% Owner X_Officer (give title Other (specify (Month/Day/Year) below) below) 420 SAW MILL RIVER ROAD 12/18/2015 Chief of Business Operations (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting ARDSLEY, NY 10502 Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities Acquired (A) 5. Amount of 7. Nature of 6. Security (Month/Day/Year) Execution Date, if Transaction Disposed of (D) Securities Ownership Indirect (Instr. 3) any Code (Instr. 3, 4 and 5) Beneficially Form: Beneficial (Month/Day/Year) Owned Direct (D) Ownership (Instr. 8) Following or Indirect (Instr. 4) Reported (\mathbf{I}) (A) Transaction(s) (Instr. 4) or (Instr. 3 and 4) Code V Amount (D) Price 17,527 Common 12/18/2015 Μ A \$6 26,729 D Stock (1) 21,499 Common 12/18/2015 \$ 5.85 D Μ A 48,228 (1) Stock \$ Common 38,506 12/18/2015 S D 40.6206 9,722 D (1) Stock (2)\$41.06 Common 520 (1) 12/18/2015 S 9.202 D D (3) Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: ACORDA THERAPEUTICS INC - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	orDerivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 6	12/18/2015		М		17,527 (<u>1)</u>	<u>(4)</u>	02/15/2016	Common Stock	17,527
Employee Stock Option (right to buy)	\$ 5.85	12/18/2015		М		21,499 (1)	<u>(5)</u>	03/17/2016	Common Stock	21,499

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
LAWRENCE DAVID 420 SAW MILL RIVER ROAD ARDSLEY, NY 10502			Chief of Business Operations					

Signatures

/s/ David 12/22/2015 Lawrence Date

Reporting Person Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1)

Edgar Filing: ACORDA THERAPEUTICS INC - Form 4

Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2016 on the expiration date reported within Table II unless exercised.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from \$40.0400 to
 (2) \$41.0319 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from \$41.0500 to
 (3) \$41.0700 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (4) The shares subject to these options vested in installments and were fully vested on February 15, 2010.
- (5) The shares subject to these options vested in installments and were fully vested on February 10, 2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.